In January 2013, a 41-year-old man presented for follow-up to our diabetes unit with jaundice, fatigue, dark urine, and stool discoloration. Four weeks earlier, he had suffered a sudden sensorineural hearing loss and was treated with a prednisolone taper scheme starting with 250 mg q.i. Fig. 1 ). Antibodies to metformin could not be detected.
As measures of hepatic synthetic function were normal and the patient was doing better after stopping metformin, watchful waiting was decided. Diabetes therapy was continued with insulin. Declining transaminases were observed as soon as the next day, but bilirubin increased until 10 days after the discontinuation of metformin. Pruritus and skin eruptions arose, and empirical treatment with ursodeoxycholic acid was started to accelerate bilirubin clearance. The symptoms subsided over the following weeks. Within 2 months, bilirubin and transaminase levels normalized. Eosinophils were still slightly elevated (4.1%). Reactivity of CD4 1 T cells 5 PBMC were incubated with metformin at concentrations 0, 10, 100, 1,000 and 10,000 mg/mL for 24 h at 378C, 5% CO 2 in a humidified atmosphere. Cell staining was performed using cocktails (Becton, Dickinson and Company, San Jose, CA) for the demonstration of activated (CD69-expressing) CD4
1 and CD8 1 T cells, CD19 1 B cells, and CD56 1 NK cells. Quadrants were set according to an isotype control. Results were expressed as an activation index dividing the percentage of CD69-expressing cells of the respective cell types with antigen exposure by that of CD69-expressing cells without antigen (metformin 0). toward metformin decreased, while that of CD19 1 B cells still persisted.
Only 13 cases of metformin-induced hepatitis have been described in the literature. Symptoms emerged 2-4 weeks after initiation of metformin and regressed after 3-12 weeks. In one case, the patient decided on his own to take a dose of 850 mg 6 weeks after he was free of complaints and within 24 h all symptoms reoccurred (1). In our case, the eosinophilia, rapid elevation of transaminases and their decrease after stopping the medication, skin eruptions, and former incrimination of metformin in similar cases made an idiosyncratic drug reaction probable.
This was confirmed by the findings of the lymphocyte activation assay. A.F. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
